Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Which Are The Toughest Diseases Area To Achieve Clinical Success In?

Executive Summary

In the last decade, on average, only one in 10 Phase I drug development programs conducted in the US have successfully advanced all the way to FDA approval. Meanwhile, despite more than a third of industry's R&D budget being spent on Phase III trials, 42% of programs fail to progress from there, according to a new report from BIO and Informa's Pharma Intelligence.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC065283

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel